 The mutation is located on a part of the protein that normally binds with the LDL receptor, and binding is reduced as a result of the mutation.Like "LDLR", the number of abnormal copies determines the severity of the hypercholesterolemia.Mutations in the proprotein convertase subtilisin/kexin type 9 ("PCSK9") gene were linked to autosomal dominant (i.e.